Haploinsufficiency of MYBPC3 exacerbates the development of hypertrophic cardiomyopathy in heterozygous mice

Journal of Molecular and Cellular Cardiology

Volumn 79, Issue , 2015, Pages 234-243

  Barefield, David ^a   Kumar, Mohit ^a   Gorham, Joshua ^b   Seidman, Jonathan G ^b   Seidman, Christine E ^b   de Tombe, Pieter P ^a   Sadayappan, Sakthivel ^a  

^a LOYOLA UNIVERSITY CHICAGO   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Cardiac myosin binding protein C; Haploinsufficiency; Hypertrophic cardiomyopathy; Mouse models; MYBPC3

Indexed keywords

CARDIAC MYOSIN; CARDIAC MYOSIN BINDING PROTEIN C; MESSENGER RNA; TROPONIN I; UNCLASSIFIED DRUG; CARRIER PROTEIN; MYOSIN-BINDING PROTEIN C;

ANIMAL CELL; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DISEASE COURSE; DISEASE EXACERBATION; DISEASE SEVERITY; DOWN REGULATION; ECHOCARDIOGRAPHY; GENE; GENE DOSAGE; GENE EXPRESSION; GENE MUTATION; HAPLOINSUFFICIENCY; HEART EJECTION FRACTION; HEART LEFT VENTRICLE FILLING; HEART MUSCLE CELL; HEART MUSCLE CONTRACTILE FORCE; HEART STRESS; HETEROZYGOSITY; HYPERTROPHIC CARDIOMYOPATHY; IN VIVO STUDY; MOUSE; MYBPC3 GENE; MYOFILAMENT; NONHUMAN; PHENOTYPE; PROTEIN CONTENT; PROTEIN EXPRESSION; PROTEIN METABOLISM; PROTEIN PHOSPHORYLATION; RNA SEQUENCE; SARCOMERE; SEQUENCE ANALYSIS; STEADY STATE; STOICHIOMETRY; SYSTOLE; UPREGULATION; WESTERN BLOTTING; ALLELE; ANIMAL; AORTA; CARDIOMYOPATHY, HYPERTROPHIC; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENETICS; HEART MUSCLE; HETEROZYGOTE; HUMAN; METABOLISM; MUTATION; PATHOLOGY; PATHOPHYSIOLOGY; PRESSURE; STENOSIS, OCCLUSION AND OBSTRUCTION;

MUS;

ALLELES; ANIMALS; AORTA; CARDIOMYOPATHY, HYPERTROPHIC; CARRIER PROTEINS; CONSTRICTION, PATHOLOGIC; DISEASE PROGRESSION; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; HAPLOINSUFFICIENCY; HETEROZYGOTE; HUMANS; MICE; MUTATION; MYOCARDIUM; MYOCYTES, CARDIAC; PRESSURE; SEQUENCE ANALYSIS, RNA; SYSTOLE;

EID: 84916917851     PISSN: 00222828     EISSN: 10958584     Source Type: Journal    
DOI: 10.1016/j.yjmcc.2014.11.018     Document Type: Article

References (46)

1. Maron B., Gardin J., Flack J., Gidding S., Kurosaki T., Bild D. Prevalence of hypertrophic cardiomyopathy in a general population of young adults: echocardiographic analysis of 4111 subjects in the CARDIA study. Circulation 1995, 92:785-789.
2. Go A.S., Mozaffarian D., Roger V.L., Benjamin E.J., Berry J.D., Blaha M.J., et al. Heart disease and stroke statistics-2014 update: a report from the American Heart Association. Circulation 2013, 129:e28-e292.
3. Morita H., Rehm H.L., Menesses A., McDonough B., Roberts A.E., Kucherlapati R., et al. Shared genetic causes of cardiac hypertrophy in children and adults. N Engl J Med 2008, 358:1899-1908.
4. Harris S.P., Lyons R.G., Bezold K.L. In the thick of it: HCM-causing mutations in myosin binding proteins of the thick filament. Circ Res 2011, 108:751-764.
5. Watkins H., Conner D., Thierfelder L., Jarcho J.A., MacRae C., McKenna W.J., et al. Mutations in the cardiac myosin binding protein-C gene on chromosome 11 cause familial hypertrophic cardiomyopathy. Nat Genet 1995, 11:434-437.
6. Bonne G., Carrier L., Bercovici J., Cruaud C., Richard P., Hainque B., et al. Cardiac myosin binding protein-C gene splice acceptor site mutation is associated with familial hypertrophic cardiomyopathy. Nat Genet 1995, 11:438-440.
7. Niimura H., Bachinski L., Sangwatanaroj S., Watkins H., Chudley A., McKenna W., et al. Mutations in the gene for cardiac myosin-binding protein c and late-onset familial hypertrophic cardiomyopathy. N Engl J Med 1998, 338:1248-1257.
8. Moolman J.A., Reith S., Uhl K., Bailey S., Gautel M., Jeschke B., et al. A newly created splice donor site in exon 25 of the MyBP-C gene is responsible for inherited hypertrophic cardiomyopathy with incomplete disease penetrance. Circulation 2000, 101:1396-1402.
9. Alcalai R., Seidman J., Seidman C. Genetic basis of hypertrophic cardiomyopathy: from bench to the clinics. J Cardiovasc Electrophysiol 2008, 19:104-110.
10. Knöll R. Myosin binding protein C: implications for signal-transduction. J Muscle Res Cell Motil 2012, 33:31-42.
11. Marston S., Copeland O., Jacques A., Livesey K., Tsang V., McKenna W.J., et al. Evidence from human myectomy samples that MYBPC3 mutations cause hypertrophic cardiomyopathy through haploinsufficiency. Circ Res 2009, 105:219-222.
12. van Dijk S., Dooijes D., dos Remedios C., Michels M., Lamers J., Winegrad S., et al. Cardiac myosin-binding protein c mutations and hypertrophic cardiomyopathy: haploinsufficiency, deranged phosphorylation, and cardiomyocyte dysfunction. Circulation 2009, 119:1473-1483.
13. McConnell B., Jones K., Farkin D., Arroyo L., Lee R., Aristizabal O., et al. Dilated cardiomyopathy in homozygous myosin-binding protein-C mutant mice. J Clin Invest 1999, 104:1235-1244.
14. Harris S., Bartley C., Hacker T., McDonald K., Douglas P., Greaser M., et al. Hypertrophic cardiomyopathy in cardiac myosin binding protein-C knockout mice. Circ Res 2002, 90:594-601.
15. Carrier L., Knoll R., Vignier N., Keller D., Bausero P., Prudhon B., et al. Asymmetric septal hypertrophy in heterozygous cMyBP-C null mice. Cardiovasc Res 2004, 63:293-304.
16. Vignier N., Schlossarek S., Fraysse B., Mearini G., Kramer E., Herve P., et al. Nonsense-mediated mRNA decay and ubiquitin-proteasome system regulate cardiac myosin-binding protein C mutant levels in cardiomyopathic mice. Circ Res 2009, 105:239-248.
17. Cheng Y., Wan X., McElfresh T., Chen X., Gresham K., Rosenbaum D., et al. Impaired contractile function due to decreased cardiac myosin binding protein C content in the sarcomere. Am J Physiol Heart Circ Physiol 2013, 305:H52-H65.
18. Barefield D., Kumar M., de Tombe P.P., Sadayappan S. Contractile dysfunction in a mouse model expressing a heterozygous MYBPC3 mutation associated with hypertrophic cardiomyopathy. Am J Physiol Heart Circ Physiol 2014, 306:H807-H815.
19. Kuster D.W., Sadayappan S. MYBPC3's alternate ending: consequences and therapeutic implications of a highly prevalent 25bp deletion mutation. Pflugers Arch 2014, 466:207-213.
20. Christodoulou D.C., Wakimoto H., Onoue K., Eminaga S., Gorham J.M., DePalma S.R., et al. 5'RNA-Seq identifies Fhl1 as a genetic modifier in cardiomyopathy. J Clin Invest 2014, 124:1364-1370.
21. Dorn G.W., McNally E.M. Two strikes and you're out: gene-gene mutation interactions in HCM. Circ Res 2014, 115:208-210.
22. Blankenburg R., Hackert K., Wurster S., Deenen R., Seidman J.G., Seidman C.E., et al. Beta-myosin heavy chain variant Val606Met causes very mild hypertrophic cardiomyopathy in mice, but exacerbates HCM phenotypes in mice carrying other HCM mutations. Circ Res 2014, 115:227-237.
23. Najafi A., Schlossarek S., van Deel E.D., van den Heuvel N., Guclu A., Goebel M., et al. Sexual dimorphic response to exercise in hypertrophic cardiomyopathy-associated MYBPC3-targeted knock-in mice. Pflugers Arch 2014, 10.1007/s00424-014-1570-7.
24. Berul C.I., McConnell B.K., Wakimoto H., Moskowitz I.P., Maguire C.T., Semsarian C., et al. Ventricular arrhythmia vulnerability in cardiomyopathic mice with homozygous mutant myosin-binding protein C gene. Circulation 2001, 104:2734-2739.
25. McConnell B.K., Fatkin D., Semsarian C., Jones K.A., Georgakopoulos D., Maguire C.T., et al. Comparison of two murine models of familial hypertrophic cardiomyopathy. Circ Res 2001, 88:383-389.
26. Sadayappan S., Gulick J., Klevitsky R., Lorenz J.N., Sargent M., Molkentin J.D., et al. Cardiac myosin binding protein-C phosphorylation in a {beta}-myosin heavy chain background. Circulation 2009, 119:1253-1262.
27. Verma S.K., Krishnamurthy P., Barefield D., Singh N., Gupta R., Lambers E., et al. Interleukin-10 treatment attenuates pressure overload-induced hypertrophic remodeling and improves heart function via signal transducers and activators of transcription 3-dependent inhibition of nuclear factor-kappaB. Circulation 2012, 126:418-429.
28. Pfaffl M. A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res 2001, 29:2002-2007.
29. Christodoulou D.C., Gorham J.M., Herman D.S., Seidman J.G. Construction of normalized RNA-seq libraries for next-generation sequencing using the crab duplex-specific nuclease. Curr Protoc Mol Biol 2011, (Chapter 4:Unit4 12).
30. Sadayappan S., Gulick J., Osinska H., Martin L.A., Hahn H.S., Dorn G.W., et al. Cardiac myosin binding protein-C phosphorylation and cardiac function. Circ Res 2005, 97:1156-1163.
31. Barefield D., Sadayappan S. Phosphorylation and function of cardiac myosin binding protein-C in health and disease. J Mol Cell Cardiol 2010, 48:866-875.
32. Sadayappan S., Osinska H., Klevitsky R., Lorenz J.N., Sargent M., Molkentin J.D., et al. Cardiac myosin binding protein-C phosphorylation is cardioprotective. Proc Natl Acad Sci U S A 2006, 103:16918-16923.
33. Sadayappan S., Gulick J., Osinska H., Barefield D., Cuello F., Avkiran M., et al. A critical function for Ser-282 in cardiac myosin binding protein-C phosphorylation and cardiac function. Circ Res 2011, 109:141-150.
34. Copeland O., Sadayappan S., Messer A.E., Steinen G.J., van der Velden J., Marston S.B. Analysis of cardiac myosin binding protein-C phosphorylation in human heart muscle. J Mol Cell Cardiol 2010, 49:1003-1011.
35. Chandra M., Dong W.J., Pan B.S., Cheung H.C., Solaro R.J. Effects of protein kinase A phosphorylation on signaling between cardiac troponin I and the N-terminal domain of cardiac troponin C. Biochemistry 1997, 36:13305-13311.
36. Frazier A.H., Ramirez-Correa G.A., Murphy A.M. Molecular mechanisms of sarcomere dysfunction in dilated and hypertrophic cardiomyopathy. Prog Pediatr Cardiol 2011, 31:29-33.
37. Tong C., Stelzer J., Greaser M., Powers P., Moss R. Acceleration of crossbridge kinetics by protein kinase A phosphorylation of cardiac myosin binding protein C modulates cardiac function. Circ Res 2008, 103:974-982.
38. Chen P., Patel J., Powers P., Fitzsumons D., Moss R. Dissociation of structural and functional phenotypes in cardiac myosin-binding protein C conditional knockout mice. Circulation 2012, 126:1194-1205.
39. 2+ sensitivity and diastolic dysfunction as early consequences of Mybpc3 mutation in heterozygous knock-in mice. J Mol Cell Cardiol 2012, 52:1299-1307.
40. Mearini G., Schlossarek S., Willis M., Carrier L. The ubiquitin-proteasome system in cardiac dysfunction. Biochim Biophys 2008, 1782:749-763.
41. Sorajja P., Elliott P.M., McKenna W.J. The molecular genetics of hypertrophic cardiomyopathy: prognostic implications. Europace 2000, 2:4-14.
42. Witayavanitkul N., Ait Mou Y., Kuster D.W., Khairallah R.J., Sarkey J., Govindan S., et al. Myocardial infarction-induced N-terminal fragment of cardiac myosin-binding protein C (cMyBP-C) impairs myofilament function in human myocardium. J Biol Chem 2014, 289:8818-8827.
43. Jeong E.M., Monasky M.M., Gu L., Taglieri D.M., Patel B.G., Liu H., et al. Tetrahydrobiopterin improves diastolic dysfunction by reversing changes in myofilament properties. J Mol Cell Cardiol 2013, 56:44-54.
44. Patel B.G., Wilder T., Solaro R.J. Novel control of cardiac myofilament response to calcium by S-glutathionylation at specific sites of myosin binding protein C. Front Physiol 2013, 4:336.
45. Dhandapany P.S., Sadayappan S., Xue Y., Powell G.T., Rani D.S., Nallari P., et al. A common MYBPC3 (cardiac myosin binding protein C) variant associated with cardiomyopathies in South Asia. Nat Genet 2009, 41:187-191.
46. Fatkin D., Seidman C.E., Seidman J.G. Genetics and disease of ventricular muscle. Cold Spring Harb Perspect Med 2014, 4:a021063.